GlaxoSmithKline, Merck KGaA officially call it quits on $4B partnership for flailing cancer drug
GlaxoSmithKline’s R&D head Hal Barron has spent his four years on the job taking swing after swing to rejuvenate the drug giant’s pipeline after years of inertia. One of Barron’s biggest swings has now blown up in his face after a key cancer drug went down in flames in the clinic.
GSK and Merck KGaA have ended their $4 billion collaboration on bintrafusp alfa, a once-promising cancer drug and the crown jewel of Barron’s pipeline rebuild efforts that has endured a spate of failures in recent months, the companies said Thursday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.